Moexa’s is a pre-clinical biotech advancing new anti-cancer and anti-fibrosis small molecule SMAD signaling therapeutics to clinic. We combine AI modeling to support traditional FDA IND requirements. Our strategy streamlines and expedites drug discovery for IND clearance and first-in-human clinical trials. We have agreed to Phase 1 trial plans with a top 5 CRO partner, and we are actively seeking to expand other partnerships and collaborations. We welcome your inquiry on how we can cooperate with you if you are interested in ground floor participation on a promising new drug discovery that could impact the sector.
Our innovations include invention of novel small molecule NCEs prepared for first time therapeutic use in humans on cancer, immuno-oncology, and fibrosis. Our unique AI SMAD heterotrimer is deployed for in-silico 3D RNA sequencing, precluding standardised in-vivo studies to refine and expedite traditional lead optimisation for design of our new drugs. Our tumor eradicating products are being tested to work as standalone therapeutics or in co-active use with other FDA approved drugs already in market.
Our IP library of over 75 global patents confirms the novelty and value of our technology. Our small molecule SMAD3 inhibition IP leads all Pharma worldwide. We have recently been awarded markush claim rights in the US, with our molecules qualified for broad use. Our IP presently cover all major markets with active expansion into secondary markets. This IP footprint captures more than 7 billion people, and 10 specified cancers and fibrosis with a collective annual therapeutic market value of US$200 billion worldwide for related products.
We are pleased to meet parties interested in further discussions.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 375 Morgan Ln,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- moexa.com
- Keywords
- Immuno-Oncology, Fibrosis, Cancer Therapeutics, SMAD3, TGF-β Signalling, LLC Therapeutics, B16-F10 Therapeutics, Pulmonary Fibrosis, Prophylactic Cancer Properties, Checkpoint Inhibitor Co-therapeutic, PD1, PLD-1, CTLA-4, US Patents, EU Patents, China Patents, Pre IND, Markush Rights IP.
- HQ
- West Haven, Connecticut
Moexa Pharmaceuticals, Inc. Questions
Moexa Pharmaceuticals, Inc.'s website is moexa.com
Moexa Pharmaceuticals, Inc.'s LinkedIn profile is https://www.linkedin.com/company/moexa
Moexa Pharmaceuticals, Inc. has
6 employees.
View email and phone details for 6
employees at Moexa Pharmaceuticals, Inc..
Moexa Pharmaceuticals, Inc.'s industry is
Pharmaceutical Manufacturing
Moexa Pharmaceuticals, Inc.'s top competitors are
Vitrocsa Australia New Zealand,
Kallyope,
New Beta Innovation New Zealand Limited,
Nenupharma Lsc,
Liberyx Therapeutics,
Nutragy,
Met Technology Gateway,
Suomen Immunologiayhdistys - Finnish Society For Immunology,
Receptor.ai,
Lipocancer.
Moexa Pharmaceuticals, Inc.'s categories are Pharmaceutical Manufacturing
Moexa Pharmaceuticals, Inc.'s founding year is 2015
